SK-03-92 Drug Kills Intracellular Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Drug Discovery
• Medicinal Chemistry

Background:

• Tuberculosis (TB) remains a global health challenge, exacerbated by drug-resistant Mycobacterium tuberculosis strains.
• Natural product screening identified a lead stilbene compound with antimycobacterial activity.
• Structure-activity relationship studies led to the development of SK-03-92, active against non-tuberculoid mycobacteria.

Purpose of the Study:

• To evaluate the antimycobacterial activity of the lead compound SK-03-92 against Mycobacterium tuberculosis.
• To assess the efficacy of SK-03-92 in killing intracellular M. tuberculosis within host cells.

Main Methods:

• Minimum Inhibitory Concentration (MIC) analysis was performed to determine the potency of SK-03-92.
• Intracellular killing assays using murine macrophage cells were conducted to evaluate efficacy against intracellular M. tuberculosis.

Main Results:

• SK-03-92 demonstrated significant activity against M. tuberculosis, with MIC values ranging from 0.39 to 6.25 μg/mL.
• The compound exhibited activity against single-drug-resistant M. tuberculosis strains.
• SK-03-92 successfully killed M. tuberculosis residing within murine macrophage cells.

Conclusions:

• The study concludes that the SK-03-92 stilbene compound possesses potent antimycobacterial activity.
• SK-03-92 demonstrates the ability to eliminate M. tuberculosis within mammalian macrophages, suggesting therapeutic potential.